Clinical Trial Update: Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Fluzoparib with or without Camrelizumab for HRD-positive, HER2-negative advanced breast cancer is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: wang shusen | Conditions: Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | Phase 2 | Status: SUSPENDED